Highlights: The second shift of the JEE Main day 1 exam has concluded. Check the details below. The exam is scheduled for ...
Q4 2024 Earnings Call Transcript January 21, 2025 Progress Software Corporation beats earnings expectations. Reported EPS is ...
Companies poured billions into fabs and facilities around the world as regions continue to build self-sufficiency and form ...
News Medical on MSN3d
Exploring the role of confocal-based high-content imaging in advancing core facilitiesIn this interview, NewsMedical speaks with Esther Kieserman and Arvonn Tully from Yokogawa Life Science about how ...
AstraZeneca and Merck & Co's Lynparza has been the undisputed market leader in the PARP inhibitor category for some years, but would-be competitors continue to chip away at its market share.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback